Wednesday, December 19, 2012

Baricitinib at the ACR 2012 in Washington

Baricitinib (also known as INCB28050, LY3009104) is an oral JAK1 and JAK2 inhibitor.
For results presented at EULAR 2012 look here:  

J. S. Smolen and colleagues looked at patient reported outcomes in patients with rheumatoid arthritis receiving baricitinib and traditional DMARDs (Abstract No. 490): “In this phase 2b study in patients with RA, those who received baricitinib reported clinically meaningful improvements as early as week 2 in most PROs relative to PBO as well as at 12 weeks.” Dear Josef S. Smolen, where have you hidden the results of DAS28, SDAI, and CDAI? What should I think, if you tell me all kinds of results but omit the important ones? Yes, my scepticism is alerted.

Another study (? – more likely to be the same study) by M. C. Genovese and colleagues (Abstract No. 2487) concluded: “Significant improvements in the signs and symptoms of RA versus placebo were observed over 12 weeks. These responses were maintained or improved for an additional 12 weeks of blinded treatment with 2 mg, 4 mg and 8 mg. In addition, safety signals observed over 12 and 24 weeks were consistent with previously conducted studies of baricitinib.” Oops, that was a close one, here is the conclusion based on ACR20, ACR50, ACR70, DAS28, and CDAI.

And a phase 2b study by Ch. G. Peterfy (Abstract No. 2499), which is a subset of the above mentioned study. Peterfy and colleagues worked on MRIs and concluded: “MRI findings in this subgroup of pts with active erosive RA suggest dose-dependent suppression of synovitis, osteitis and total inflammation by baricitinib for the 4-mg and 8-mg groups at 12 and 24 weeks.”
To sum it up: Baricitinib, we’re waiting for you!


I've just looked at the PeerVoice update by Prof. Ronald F. van Vollenhoven: "Recent Efficacy Data on JAK Inhibitors: How Well Will They Work for Your Patients?"

Followed by Prof. Juan J. Gomez-Reino with: "New Data on the Safety of JAK Inhibitors"

So, we're waiting for new data to be discussed at the EULAR 1013 meeting in Madrids.

And the EULAR 2013 data is discussed here:

No comments:

Post a Comment